Baseline Montreal Cognitive Assessment Score Research Articles

Cognitive Trajectories Following Acute Infection in Older Patients With and Without Cognitive Impairment: An 1-Year Follow-Up Study.

Introduction: Dementia is a known risk factor for both delirium and acute systemic infections which may also play a significant role in promoting or accelerating neurodegenerative disease. Infections are both the main causes of hospitalization of dementia patients and can be a major precipitant of delirium but currently it is not possible to predict the risk of cognitive decline in older patients exposed to acute infection.Objectives: We aimed to determine the level of cognitive change at 1-year follow up in individuals with different patterns of cognitive function (dementia, delirium, delirium superimposed on dementia) at the time of their hospitalization due to a systemic infection and to correlate these cognitive patterns with clinical status variables.Methods: We recruited 53 hospitalized geriatric patients with a systemic infection, and we collected 12-months follow up data for 34 patients. These patients were classified in four groups: no cognitive impairment (controls—C), delirium only (D), dementia only (Dem), and delirium superimposed to dementia (DD). Cognitive performance was measured by change in score on the Montreal Cognitive Assessment (MoCA) and delirium was identified using Confusion Assessment Measure (CAM). We examined performance on the MoCA in the first year after hospitalization, controlling for demographic characteristics, coexisting medical conditions, and type of infection.Results: For the 34 patients to whom follow-up data was available, delirium presence in individuals with prior dementia (DD group) was associated with a negative mean change score of 3-point (p < 0.02) at 1 year follow up, whereas dementia patients without delirium had a mean change score of 1.5-point lower at 12-months (p = 0.04), when comparing follow-up and baseline MoCA scores. Cognitively healthy patients did not significantly decrease their MoCA score at follow-up (p = 0.15). MoCA and NPI scores during hospitalization were significantly correlated with the level of cognitive decline in the four groups (r = 0.658, p < 0.01 and r = 0.439, p = 0.02, respectively).Conclusions: Premorbid dementia and delirium superimposed on dementia during hospitalization in older patients with acute infections predict cognitive decline at 1 year following admission. Taken together, our findings suggest a pathophysiological interaction between neurodegenerative changes, acute infection, and delirium.

Cardiovascular risk moderates aerobic exercise efficacy on executive function in subcortical ischemic vascular cognitive impairment

AbstractBackgroundAerobic exercise can promote cognitive function in adults with Subcortical Ischemic Vascular Cognitive Impairment (SIVCI) by modifying cardiovascular risk factors. However, one’s cardiovascular health may attenuate the benefits of aerobic exercise on cognitive outcomes in SIVCI. We examined whether baseline Framingham Cardiovascular Risk Profile Score (FCRP) moderates the effect of a 6‐month progressive aerobic exercise program on executive function in adults with SIVCI.MethodA secondary analysis of a proof‐of‐concept randomized controlled trial in 71 adults, who were randomized to either: 1) 3x/week progressive aerobic exercise program (AT); or 2) education program (CON). Three executive processes were measured: 1) response inhibition by Stroop Colour Word Test; 2) working memory by digits backward test, and 3) set shifting by the Trail Making Test (B‐A). Baseline cardiovascular risk was calculated using the FCRP, and participants were classified as either low risk (&lt;20% FCRP score; LCVR) or high risk (&gt;20% FCRP score; HCVR). A complete case analysis (n=57) was conducted using an analysis of covariance (ANCOVA) to evaluate between‐group differences in the three executive processes. Age, baseline Montreal Cognitive Assessment score, education, and baseline score for the outcome variable were entered as covariates in all models.ResultA significant interaction was found between FCRP and group (AT or CON) for the digit span backward (F(1,49)=4.67, p=0.03) and the Trail Making Test (F(1,50)=4.09, p=0.04). On the digit span backward test, AT improved performance compared to CON (3.74±.33 vs. 2.75±.46) in those with LCVR, while in those with HCVR, AT did not improve performance compared to CON (2.97±.45 vs. 3.76±.41). Similarly, for the Trail Making Test (B‐A), AT improved performance compared to CON (52.66±13.27 vs. 80.12±17.82) in those with LCVR, while AT was not beneficial compared to CON in those with HCVR (98.80±18.06 vs. 59.92±17.09).ConclusionBaseline cardiovascular risk significantly moderates the efficacy of aerobic exercise on working memory and set shifting in adults with SIVCI. Our findings highlight the importance of intervening early in the disease course of SIVCI, when cardiovascular risk may be lower, to reap maximum benefits of aerobic exercise.

Exercise training improves cognition in chronic stroke: A 6‐month randomized controlled trial

AbstractBackgroundA stroke doubles one’s risk for dementia. Impairment in multiple domains of cognition are common following stroke. Thus, stroke survivors represent a target population in need of intervention strategies to promote cognitive function and prevent dementia. We assessed whether targeted exercise training or cognitive and social enrichment activities would promote cognitive function in community‐dwelling adults with chronic stroke (i.e., &gt; 12 months since stroke event).MethodsA three‐arm parallel, single‐blinded, 6‐month randomized controlled trial with 120 adults with chronic stroke who were randomized (2:2:3) to: 1) targeted exercise training (EX; n=34)) modeled after the Fitness And Mobility Exercise (FAME) program (Eng, Top Geriatr Rehabil, 2010); 2) cognitive and social enrichment activities (Cog‐Plus; n=34); and 3) an active control group (CON; n=52). Each experimental arm was group‐based and 2x/week. The primary outcome was the ADAS‐Cog‐Plus, a global measure of cognitive performance using multidimensional item response theory to summarize scores from the 13‐item ADAS‐Cog and other standard cognitive assessments (i.e., Trail Making Test Parts A and B, Digit Span Forward and Backward, and Animal and Vegetable Fluency). Lower ADAS‐Cog‐Plus scores represent better cognitive performance; ADAS‐Cog‐Plus scores of approximately −1.0 indicate healthy cognitive performance, 0.0 indicate mild cognitive impairment, and 1.0 indicate dementia. The primary analysis using linear mixed model compared changes in ADAS‐Cog‐Plus performance from baseline to month 6, with baseline ADAS‐Cog‐Plus and Mini‐Mental State Examination scores as covariates. Two planned simple contrasts (i.e., EX vs. CON; Cog‐Plus vs. CON) were performed using the Dunnett test.ResultMean baseline Fugl‐Meyer score was 81.21 (SD=23.85; range: 6‐100) and mean baseline Montreal Cognitive Assessment score was 21.89 points out of 30. An overall attrition rate of 14% was observed (EX=6; Cog‐Plus=5; CON=6). Participants in the EX group had significantly better ADAS‐Cog Plus performance than CON at trial completion (estimated mean difference: ‐0.23; 95%CI:[‐0.43, ‐0.03]; p=.024). There was no significant difference in ADAS‐Cog Plus performance between the Cog‐Plus and CON group at trial completion (estimated mean difference: ‐0.10; 95% CI:[‐0.30, 0.10]; p=.314).ConclusionTargeted exercise training may be efficacious in improving cognition in adults with chronic stroke and should be promoted among individuals with chronic stroke.

Favorable cognitive effects of the BET protein inhibitor apabetalone in patients 70 and older

AbstractBackgroundCognitive decline in late life including Alzheimer’s disease (AD) and vascular dementia (VaD) may be caused by epigenetic change. Bromodomain and extra‐terminal (BET) proteins are epigenetic transcriptional “readers” found to contribute to chronic disease. Apabetalone, a small molecule BET protein inhibitor for oral administration, was assessed for therapeutic effects on cognitive performance in a randomized trial of patients at high risk for cardiovascular disease (CVD).MethodIn the BETonMACE post‐Acute Coronary Syndrome trial in type 2 diabetes mellitus patients were randomized to apabetalone capsule 100 mg b.i.d. or placebo (n=2425). The Montreal Cognitive Assessment (MoCA) was performed on all patients 70 years or older at baseline (n=464) and yearly in the embedded cognition study. In a prespecified analysis, participants were assigned to one of three groups: MoCA score ≥ 26 (normal performance), MoCA score 25 – 22 (mild cognitive impairment), and MoCA score ≤ 21 (dementia).ResultApabetalone exposure was equivalent in each of the three MoCA‐score defined groups. Apabetalone treatment over approximately two years was associated with an increased total MoCA score in participants with baseline MoCA score of ≤ 21 (p = 0.02). Onset of cognition benefit appeared after 12 months treatment. There was no significant difference in change from baseline in the treatment groups with higher MoCA scores.ConclusionIn the BETonMACE trial epigenetic BET protein inhibition by apabetalone capsule 100 mg b.i.d. vs placebo was associated with improved cognition as measured by MoCA in patients with baseline scores of &lt; 21. It is feasible to embed cognition assessment in randomized Phase 3 CVD endpoint studies. BET protein inhibitors warrant further investigation for late life cognitive disorders.

Post-stroke cognitive impairment: screening with MMSE and MoCA and predictors of their persistence after treatment at the Stroke Center

Objective — to analyze the results of screening for post‑stroke cognitive impairment (PCI) in patients with cerebral stroke (CS) admitted to the Stroke Center (SC) in different disease phases, and to determine independent predictors of the PCI persistence at discharge.&#x0D; Methods and subjects. 399 patients were enrolled, including 242 (60.7 %) men and 157 (39.3 %) women with the median age was 66.2 years (IQR 58.5 — 76.3). IS was diagnosed in 331 (82.9 %), and ICH in 68 (17.1 %) patients. Among patients with IS, 137 (41.4 %) had an atherothrombotic subtype, 152 (46.0 %) had a cardioembolic subtype, 21 (6.3 %) had a lacunar subtype, another 21 (6.3 %) had another or unknown cause of stroke. Patients were screened for PCI using the Mini‑Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) on admission and at discharge. Participants with MMSE score of 0 — 24 or a MoCA score of 0 — 25 were considered having PCI. Upon admission, all patients were assessed using the National Institutes of Health Stroke Scale (NIHSS), Bartel Index, and Modified Rankine Scale (mRS). The method of constructing and analyzing logistic regression models was used to determine independent predictors of the preservation of PCI at discharge. The analysis was carried out using the MedCalc v. 19.1.&#x0D; Results. The baseline NIHSS score ranged from 0 to 39 (median 11, IQR 6 — 18). The majority (64.2 %) of the subjects were hospitalized within the first 30 days from the CS onset. The MMSE score on admission ranged from 0 to 30 (median 20, IQR 2 — 27), and in 179 (44.9 %) of the patients the initial score was 0 to 17 (severe PCI), whereas in 61 (15 3 %) of the participants it was 18 to 24 (moderately severe PCI) and only 159 (39.8 %) persons scored 25 to 30 (no PCI). The baseline MoCA score ranged from 0 to 30 (median 15, IQR 1 — 24), and 356 (89.2 %) patients were shown to have PCI (score 0 to 25). According to screening with MMSE at discharge, 125 (31.4 %) patients had severe PCI, and 67 (16.8 %) had moderately severe PCI. The MoCA assessment before discharge indicated PCI in 324 (81.2 %) patients. According to both MMSE and MoCA, the rate of PCI on admission was significantly higher than at discharge (p &lt; 0.001). Among the 240 patients who had PCI according to MMSE score, 239 (99.6 %) had PCI according to the MoCA score. However, among 159 patients who screened negative for PCI with MMSE at admission, 117 (73.6 %) screened positive with MoCA. Screening results using both MMSE and MoCA were not significantly associated with affected hemisphere. ICH was associated with lower (p &lt; 0.0001) MMSE and MoCA scores compared with IS. Predictors of PCI according to MMSE score at discharge were a longer time interval from CS onset to SC admission, and a lower baseline MMSE score. However, with MoCA, the predictors were AT subtype IS, lesions in the distribution of the right or both middle cerebral arteries, older patient age, and a lower baseline MoCA score.&#x0D; Conclusions. In patients with MI, a high rate of PCI was documented on admission, but was significantly lower at discharge. In patients with established PCI, according to MMSE score, the use of MoCA for screening seems useless, however, screening with MoCA identified PCI in 3/4 in patients with a normal MMSE score. The independent predictors of scores on these two scales, indicating PCI, were significantly different, so they should not be considered interchangeable.

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.

Background:Epigenetic changes may contribute importantly to cognitive decline in late life including Alzheimer’s disease (AD) and vascular dementia (VaD). Bromodomain and extra-terminal (BET) proteins are epigenetic “readers” that may distort normal gene expression and contribute to chronic disorders.Objective:To assess the effects of apabetalone, a small molecule BET protein inhibitor, on cognitive performance of patients 70 years or older participating in a randomized trial of patients at high risk for major cardiovascular events (MACE).Methods:The Montreal Cognitive Assessment (MoCA) was performed on all patients 70 years or older at the time of randomization. 464 participants were randomized to apabetalone or placebo in the cognition sub-study. In a prespecified analysis, participants were assigned to one of three groups: MoCA score≥26 (normal performance), MoCA score 25–22 (mild cognitive impairment), and MoCA score≤21 (dementia). Exposure to apabetalone was equivalent in the treatment groups in each MoCA-defined group.Results:Apabetalone was associated with an increased total MoCA score in participants with baseline MoCA score of≤21 (p = 0.02). There was no significant difference in change from baseline in the treatment groups with higher MoCA scores. In the cognition study, more patients randomized to apabetalone discontinued study drug for adverse effects (11.3% versus 7.9%).Conclusion:In this randomized controlled study, apabetalone was associated with improved cognition as measured by MoCA scores in those with baseline scores of 21 or less. BET protein inhibitors warrant further investigation for late life cognitive disorders.

Robust demographically-adjusted normative data for the Montreal Cognitive Assessment (MoCA): Results from the systolic blood pressure intervention trial

Objectives: To generate robust, demographically-adjusted regression-based norms for the Montreal Cognitive Assessment (MoCA) using a large sample of diverse older US adults. Methods: Baseline MoCA scores were examined for participants in the Systolic Blood Pressure Intervention Trial (SPRINT). A robust, cognitively-normal sample was drawn from individuals not subsequently adjudicated with cognitive impairment through 4 years of follow-up. Multivariable Beta-Binomial regression was used to model the association of demographic variables with MoCA performance and to create demographically-stratified normative tables. Results: Participants’ (N = 5,338) mean age was 66.9 ± 8.8 years, with 35.7% female, 63.1% White, 27.4% Black, 9.5% Hispanic, and 44.5% with a college or graduate education. A large proportion scored below published MoCA cutoffs: 61.4% scored below 26 and 29.2% scored below 23. A disproportionate number falling below these cutoffs were Black, Hispanic, did not graduate from college, or were ≥75 years of age. Multivariable modeling identified education, race/ethnicity, age, and sex as significant predictors of MoCA scores (p<.001), with the best fitting model explaining 24.4% of the variance. Model-based predictions of median MoCA scores were generally 1 to 2 points lower for Black and Hispanic participants across combinations of age, sex, and education. Demographically-stratified norm-tables based on regression modeling are provided to facilitate clinical use, along with our raw data. Conclusion: By using regression-based strategies that more fully account for demographic variables, we provide robust, demographically-adjusted metrics to improve cognitive screening with the MoCA in diverse older adults.

Risk factors for delayed-onset dementia after stroke or transient ischemic attack-A five-year longitudinal cohort study.

Stroke not only substantially increases the risk of incident dementia early after stroke but also the risk remains elevated years after. We aimed to determine the risk factors of dementia onset more than three to six months after stroke or transient ischemic attack. This is a single-center prospective cohort study. We recruited consecutive subjects with stroke/transient ischemic attack without early-onset dementia. We conducted an annual neuropsychological assessment for five years. We investigated the association between baseline demographic, clinical, genetic (APOEɛ4 allele), and radiological factors as well as incident recurrent stroke with delayed-onset dementia using Cox proportional hazards models. In total, 1007 patients were recruited, of which 88 with early-onset dementia and 162 who lost to follow-ups were excluded. Forty-nine (6.5%) out of 757 patients have incident delayed-onset dementia. The presence of ≥3 lacunes, history of ischemic heart disease, history of ischemic stroke, and a lower baseline Hong Kong version of the Montreal Cognitive Assessment (MoCA) score were significantly associated with delayed-onset dementia. APOEɛ4 allele, medial temporal lobe atrophy, and recurrent stroke were not predictive. The presence of ≥3 lacunes, history of ischemic heart disease, history of ischemic stroke, and a lower baseline MoCA score are associated with delayed-onset dementia after stroke/transient ischemic attack.

Effect of the complex physical therapy on the upper extremity function, functional independence and cognition in post-stroke patients

Motor dysfunction and cognitive impairment (CI) are the most prevalent and disabling among the stroke consequences. CI decreases the effectivity of motor rehabilitation, but motor dysfunction itself may also influence the manifestations and progression of CI. So development and study of novel physical therapy tactics, which are aiming to target both of these syndromes, becomes a subject of great interest nowadays.&#x0D; The aim of study was to evaluate the impact of different physical therapy approaches on the upper extremity function, cognition and functional independence in patients in 1 year after ischemic stroke.&#x0D; Materials and methods. Totally there were 72 patients examined in the 1-year period after first-ever anterior circulation ischemic stroke. Neurological status, upper extremity function and functional independence were assessed with the National Institutes of Health Stroke Scale (NIHSS), Fugl-Meyer assessment (FMA), modified Rankin Scale (mRS) and the Functional Independence Measurement (FIM). Cognitive function was assessed with the Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), Trail-making Test A and B tests (TMT). Patients in Group 1 received secondary stroke prevention therapy and performed the exercises complex for general muscle function improvement for 2 months; patients in Group 2 also performed the exercise complex for paretic hand function improvement for 2 months.&#x0D; Results. After 2 months of physical therapy a significant increase of the FIM “Self-care”, “Transfer” and therefore subtotal motor and total scores was observed in patients in Group 2; in Group 1 significant improvement was observed only in “Transfer” and subtotal motor scores. Adding of the hand exercise to the physical therapy complex (Group 2) appeared to be more beneficial for the upper extremity motor function. Patients in Group 2 after 2 months showed increase of the FMA “Wrist” score by 40 % (p&lt;0.05), “Hand” score by 42.8 % (p&lt;0.01) and “Total motor function” by 30.1 % (p&lt;0.05), and the “Total motor function” score in Group 2 was 10.9 % higher in comparison with the Group 1 (p&lt;0.05). In cognitive status significant differences compared to baseline level were observed only in Group 2; MoCA score increased by 14.3 % (p&lt;0.05) and TMT-B performance time decreased by 14.8 % (p&lt;0.05). Baseline MoCA score correlated with FMA “Wrist” (r=0.32; p=0.028), “Hand” (r=0.49; p=0.001) and “Total motor function” (r=0.46; p=0.004) scores. TMT-B score showed significant correlation with the FMA “Wrist” (r=-0.032; p=0.025), “Hand” (-0.45; p=0.009), “Speed/coordination” (r=-0.023; p=0.036) and “Total motor function” (r=-0.42; p=0.023).&#x0D; Conclusion. Adding of exercise for hand function improvement into the physical therapy complex for post-stroke patients contributes to better upper extremity motor performance and therefore is more favourable for patients’ functional independence. Upper extremity motor impairment, especially hand and wrist dysfunction, are associated with worse cognitive performance. Hand function and fine motor skills improvement could be beneficial for the patients’ cognition. Further research is needed in regard to the prognostic significance of these findings and their impact on the treatment and rehabilitation strategies.

Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC)

PurposeTo identify trajectories of cognitive performance up to five years since diagnosis and their predictors, in a cohort of patients with breast cancer (BCa). MethodsA total of 464 women with BCa admitted to the Portuguese Institute of Oncology, Porto, during 2012, were evaluated with the Montreal Cognitive Assessment (MoCA) before any treatment, and after one, three and five years. Probable cognitive impairment (PCI) at baseline was defined based on normative age- and education-specific reference values. Mclust was used to define MoCA trajectories. Receiver Operating Characteristic curves were used to assess the predictive accuracy for cognitive trajectories. ResultsTwo trajectories were identified, one with higher scores and increasing overtime, and the other, including 25.9% of the participants, showing a continuous decline. To further characterize each trajectory, participants were also classified as scoring above or below the median baseline MoCA scores. This resulted in four groups: 1) highest baseline scores, stable overtime (0.0% with PCI); 2) lowest baseline scores (29.5% with PCI); 3) mid-range scores at baseline, increasing overtime (10.5% with PCI); 4) mid-range scores at baseline, decreasing overtime (0.0% with PCI). Adding the change in MoCA during the first year to baseline variables significantly increased the accuracy to predict the downward trajectory (area under the curve [AUC] = 0.732 vs. AUC = 0.841, P < 0.001). ConclusionFour groups of patients with BCa with different cognitive performance trends were identified. The assessment of cognitive performance before treatments and after one year allows for the identification of patients more likely to have cognitive decline in the long term.

How impaired is too impaired? Exploring futile neuropsychological test patterns as a function of dementia severity and cognitive screening scores.

Some older adults cannot meaningfully participate in the testing portion of a neuropsychological evaluation due to significant cognitive impairments. There are limited empirical data on this topic. Thus, the current study sought to provide an operational definition for a futile testing profile and examine cognitive severity status and cognitive screening scores as predictors of testing futility at both baseline and first follow-up evaluations. We analysed data from 9,263 older adults from the National Alzheimer's Coordinating Center Uniform Data Set. Futile testing profiles occurred rarely at baseline (7.40%). There was a strong relationship between cognitive severity status and the prevalence of futile testing profiles, χ2 (4)=3559.77, p<.001. Over 90% of individuals with severe dementia were unable to participate meaningfully in testing. Severity range on the Montreal Cognitive Assessment (MoCA) also demonstrated a strong relationship with testing futility, χ2 (3)=3962.35, p<.001. The rate of futile testing profiles was similar at follow-up (7.90%). There was a strong association between baseline dementia severity and likelihood of demonstrating a futile testing profile at follow-up, χ2 (4)=1513.40, p<.001. Over 90% of individuals with severe dementia, who were initially able to participate meaningfully testing, no longer could at follow-up. Similarly, there was a strong relationship between baseline MoCA score band and likelihood of demonstrating a futile testing profile at follow-up, χ2 (3)=1627.37, p<.001. Results can help to guide decisions about optimizing use of limited neuropsychological assessment resources.

Longitudinal changes in MoCA performances in patients with mild cognitive impairment and small vessel disease. Results from the VMCI-Tuscany Study

The Montreal Cognitive Assessment (MoCA) is a cognitive screening test largely employed in vascular cognitive impairment, but there are no data about MoCA longitudinal changes in patients with cerebral small vessel disease (SVD). We aimed to describe changes in MoCA performance in patients with mild cognitive impairment (MCI) and SVD during a 2-year follow-up, and to evaluate their association with transition to major neurocognitive disorder (NCD). Within the prospective observational VMCI-Tuscany Study, patients with MCI and SVD underwent a comprehensive clinical, neuropsychological, and functional evaluation at baseline, and after 1 and 2 years. Among the 138 patients (mean age 74.4±6.9 years; males: 57%) who completed the study follow-up, 44 (32%) received a major NCD diagnosis. Baseline MoCA scores (mean±SD) were lower in major NCD patients (20.5±5) than in reverter/stable MCI (22.2±4.3), and the difference approached the statistical threshold of significance (p=.051). The total cohort presented a decrease in MoCA score (mean±SD) of -1.3±4.2 points (-2.6±4.7 in major NCD patients, -0.7±3.9 in reverter/stable MCI). A multivariate logistic model on the predictors of transition from MCI to major NCD, showed MoCA approaching the statistical significance (OR=1.09, 95% CI=1.00-1.19, p=.049). In our sample of MCI patients with SVD, longitudinal changes in MoCA performances were consistent with an expected more pronounced deterioration in patients who received a diagnosis of major NCD. MoCA sensitivity to change and predictive utility need to be further explored in VCI studies based on larger samples and longer follow-up periods.

Effect of Art Therapy on Cognitive and Psychological Well-being of Patients with Major Mental Disorders- An Experimental Study

Introduction: Psychological and recreational activities have been found to be useful in the field of psychiatry. ‘Art Therapy’ uses therapeutic use of art within the professional role in the personal development of the patient by creating art and finding meaning through them. People can improve their awareness of self and cope with symptoms of stress, anxiety, and traumatic experiences. They can also improve cognitive abilities and gain pleasure in making art. Aim: To evaluate the effectiveness of art therapy on cognitive functions and psychological well-being among mentally ill patients admitted with major mental disorders. Materials and Methods: An evaluative approach with a pre- experimental, one group pre and post-test design was adopted to select 60 patients admitted with major mental disorders in a selected psychiatric unit, Udupi, Karnataka, India through purposive sampling technique. Data collection was done from 1st December 2019 to 31st January 2020. Information was collected through Montreal Cognitive Assessment (MoCA) Scale and Psychological General Well-being Index (PGWBI) Scale. The pretest was conducted on the first day. Art therapy sessions were conducted for four consecutive days. Post-test assessments were done on the seventh and fourteenth day. Results: The mean baseline MoCA score was 16.70±4.04 which improved to 19.10±4.07 on 7th day and 21.28±4.33 on 14th day. Similarly, baseline score of PGWBI was 35.28±13.94 which improved to 53.58±13.88 on 7th day and further increased to 81.80±17.69. Conclusion: Art therapy has a strong effect on the psychological well-being of the patients with mental illnesses and is effective in improving cognitive functions and psychological well-being.

Investigating the relationship between neuropsychiatric symptoms and cognition in mild cognitive impairment and Alzheimer’s disease patients undergoing an exercise‐primed transcranial direct current stimulation clinical trial (The EXPRESS Study)

AbstractBackgroundNeuropsychiatric symptoms (NPS) are common features of Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD), and are associated with poorer cognition. Transcranial direct current stimulation (tDCS), a non‐invasive type of brain stimulation, has been investigated for the treatment of some NPS in a few small AD studies, but with negative results for apathy and depression. Priming the brain with an excitatory intervention, such as exercise, may elicit greater changes if applied prior to tDCS. Using data from an ongoing blinded study, we aimed to evaluate the relationship between NPS and cognition in MCI and mild AD.MethodMCI or mild AD participants were enrolled in a two‐week, randomized, blinded clinical trial investigating the effects of exercise‐primed tDCS for cognition using the Montreal Cognitive Assessment (MoCA). NPS were measured using the Neuropsychiatric Inventory (NPI) subscales. A Pearson’s correlation determined the relationship between NPI scores and the MoCA at baseline in patients who received exercise‐primed tDCS or tDCS alone. A repeated measures analysis of variance compared changes in NPI scores between the two treatment groups over time. As the study is ongoing, the treatment groups have been randomly coded as Group 1 and Group 2 to avoid unblinding.ResultAt baseline, participants (N=13) were 76.5±7.2 years of age, MoCA score= 20.9±3.6, 53% female, and 53% MCI. Nine (69.2%) participants reported having at least one NPS (NPI Score ≥ 1). Apathy (46.2%), sleep disturbances (38.5%), agitation (30.8%), and anxiety (30.8%) were the most prevalent NPS. At baseline, only anxiety was negatively correlated with MoCA scores (r=‐0.57, p=0.041; Figure 1). There were no significant differences between treatment groups on anxiety scores over time (F(1,10)= 2.4, p=0.16). However, after controlling for baseline MoCA scores, there was a significantly greater reduction on anxiety scores in Group 1 (‐0.83±1.3) compared to Group 2 over time (0±0; F(1,9)= 5.3, p=0.047).ConclusionRecruitment is ongoing (total N=30). Only anxiety was associated with poorer cognition at baseline. There were differences between treatment groups on anxiety scores over time, after controlling for baseline MoCA scores. It remains to be seen, after unblinding, whether the group with reduction in anxiety was receiving the primed intervention.

Patients with pretreatment leukoencephalopathy and older patients have more cognitive decline after whole brain radiotherapy

PurposeTo investigate predictors of cognitive decline after whole brain radiotherapy (WBRT) for brain metastases.MethodsA secondary analysis of a phase 2 clinical trial was conducted in patients who received stereotactic radiosurgery for 1–10 brain metastases and WBRT (NCT01046123). The Montreal Cognitive Assessment (MoCA) was performed at baseline and every 3 months after WBRT. Baseline T2-weighted fluid attenuation inversion recovery magnetic resonance imaging was independently assessed by two neuroradiologists for the presence of white matter hyperintensities (WMH) using the Fazekas visual rating scale. WMH were also manually segmented for volumetric analysis. Univariable and multivariable logistic regression were used to test the association between baseline variables and MoCA score decline.ResultsForty-six patients survived ≥ 3 months after treatment. Age (OR 1.12 (1.04–1.21), p < 0.01), baseline WMH volume (OR 1.20, 95% CI 1.06–1.52, p = 0.02) and baseline Fazekas score ≥ 3/6 (OR 6.4, 95% CI 1.7–24.7, p < 0.01) were predictive of MoCA score decline. In multivariable analysis, age was the only significant predictor of MoCA decline. However, all three patients with pre-treatment leukoencephalopathy (Fazekas score = 6/6) had notable adverse outcomes due to cognitive impairment: one required full-time home nursing support and two were institutionalized.ConclusionA greater decline in cognition after WBRT was observed in older patients and patients with a higher baseline WMH burden. Although this study is small and hypothesis-generating, we propose that radiation oncologists should exercise caution in prescribing WBRT if leukoencephalopathy is present on pre-treatment imaging.Trial Registration: clinicaltrials.gov identifier NCT01046123. First posted January 11, 2010. https://clinicaltrials.gov/ct2/show/NCT01046123

Evaluation of the Mini-Mental State Examination and the Montreal Cognitive Assessment for Predicting Post-stroke Cognitive Impairment During the Acute Phase in Chinese Minor Stroke Patients

Objective: To assess the value of the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) during acute phase in predicting post-stroke cognitive impairment (PSCI) at 3–6 months.Methods: We prospectively recruited 229 patients who had suffered their first-ever ischemic stroke. PSCI was determined in 104 of these patients by a comprehensive neuropsychological battery performed at 3–6 months. Receiver operating characteristic (ROC) curve analysis was then performed to compare the discriminatory ability of the MMSE and MoCA. Also, we applied a decision tree generated by the classification and regression tree methodology.Results: In total, 66 patients had PSCI when evaluated 3–6 months after the onset of minor stroke. Logistic regression analysis revealed that education, body mass index (BMI), and baseline MoCA scores were independently associated with PSCI. ROC curve analysis showed that the ability to predict PSCI was similar when compared between baseline MoCA scores [area under curve (AUC), 0.821; 95% confidence interval (CI), 0.743–0.898] and baseline MMSE scores (AUC, 0.809; 95% CI, 0.725–0.892, P = 0.75). Both MMSE and MoCA exhibited similar predictive values at their optimal cut-off points (MMSE ≤27; sensitivity, 0.682; specificity, 0.816; MoCA ≤21; sensitivity, 0.636; specificity, 0.895). Classification and regression tree-derived analysis yielded an AUC of 0.823 (sensitivity, 0.803; specificity, 0.842).Conclusion: When applied within 2 weeks of stroke, the MMSE and MoCA are both useful and have similar predictive value for PSCI 3–6 months after the onset of minor stroke.

Cognitive outcomes after unruptured intracranial aneurysm treatment with endovascular coiling

BackgroundWe aimed to determine the effects of endovascular coiling of unruptured intracranial aneurysms (UIAs) on cognition to inform treatment decisions. We present the first study using the Montreal Cognitive Assessment...

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC.

Abiraterone acetate plus prednisone (AA+P) has shown to significantly improve survival. COSMiC, a Canadian Observational Study in Metastatic Cancer of the Prostate, set out to prospectively amass real-world data on metastatic castration-resistant prostate cancer (mCRPC) patients managed with AA+P in Canada. Herein, we report their patient-reported outcomes (PROs). After a median followup of 67.1 weeks, 254 patients were enrolled across 39 sites. Functional Assessment of Cancer Therapy-Prostate (FACT-P), Montreal Cognitive Assessment (MoCA), Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), and Current Health Satisfaction in Prostate Cancer (CHS-PCa) were evaluated at baseline, as well as at weeks 12, 24, 48, and 72 after AA+P initiation. Descriptive analysis was used with continuous variables. Changes from baseline were summarized using mean (standard deviation [SD]). At a median age of 76.6 (8.94), baseline FACT-P total score was 111.3 (19.56) with no significant change in their functional status observed from baseline over time. The median baseline MoCA score was 25.2 (4.52), yet subsequent assessments showed an absence of cognitive decline while under treatment. Similarly, no meaningful changes were detected in BPI, BFI, and CHS-PCa during the 72-week study period, thus suggesting that patients' PROs were well-maintained throughout AA+P treatment. Prostate-specific antigen (PSA) response with >50% decline was 66.4%. Safety profile was consistent with the known side effect of AA+P. COSMiC represents the largest Canadian mCRPC cohort treated with AA+P with real-world, prospective evaluation of PROs. This data demonstrated the maintenance in quality of life and cognitive status over the course of the study and underscores the importance of PRO use in this complex patient population.

Carotid Endarterectomy Is Associated With Postoperative Neurocognitive Improvement in Both Symptomatic and Asymptomatic Patients

While stroke after carotid endarterectomy (CEA) is rare, magnetic resonance imaging shows that “silent” microinfarctions after surgery are much more common. These microinfarcts have been correlated with neurocognitive decline. However, there is also evidence that revascularization may improve overall cognition due to improved cerebral blood flow and elimination of embolic source. As part of a trial of remote ischemic preconditioning as a possible neuroprotective mechanism during CEA, we examined the overall impact of carotid revascularization on cognitive function. This is an interim noncomparative analysis of the cohort enrolled in an institutional randomized trial for the role of remote ischemic preconditioning for CEA (RIP-CEA, NCT02808754). All patients underwent baseline neurocognitive testing using the Montreal-Cognitive Assessment (MoCA) and National Institutes of Health Toolbox (Flanker Inhibitory Control and Attention Test, the Dimensional Change Card Sort Test, and the Pattern Comparison Processing Speed Test). These tests specifically assess executive function and processing speed. MoCA was also conducted on postoperative day 1 in the hospital. The full neurocognitive testing battery was conducted again at the 1-month follow-up in the office. Score changes from baseline were examined at the follow-up time points. Eighty patients with a mean age of 71.3 ± 7.1 years (65% male, and 30% symptomatic) were enrolled. The average baseline MoCA score was 24.7 ± 2.8 and this was similar between symptomatic and asymptomatic patients (P = .6). Forty-seven percent of patients met criteria for cognitive decline (MoCA < 26) at baseline. While MoCA scores remained unchanged immediately postoperatively, patients experienced significant improvements in MoCA scores by 1 month after CEA (average MoCA score of 26.3 and only 26% qualifying as cognitive decline; P < .001). Similarly, patients experienced significant improvements in executive function (26.4 ± 4.7 months before CEA vs 28.3 ± 2.3 1 months after CEA; P < .001) and processing speed at 1 month after CEA (31.8 ± 9.2 months before CEA vs 35.8 ± 8.4 1 months after CEA; P < .001) as assessed by the National Institutes of Health toolbox. There was no difference in the number or degree of cognitive improvement between symptomatic and asymptomatic patients. Statin use was a significant predictor of improvement on MoCA score at 1 month (OR, 3.9; P < .05). Carotid revascularization with CEA is associated with significant improvements in neurocognitive function by one month post operatively across multiple domains. Statin use may be further protective. Longer term follow-up is needed to see the magnitude and durability of these cognitive improvements. Neurocognitive improvement following CEA may justify reconsideration of the role of carotid revascularization in asymptomatic patients.

Abstract 68: Impaired Perfusion in Intracranial Atherosclerotic Disease Predicts Cognitive Outcomes

Background: Poor collateral circulation and hypoperfusion may lead to recurrent stroke in intracranial atherosclerotic disease (ICAD). The role of perfusion in silent strokes and potentially insidious cognitive impairment in ICAD is unknown. We used evidence of impaired perfusion at angiography in SAMMPRIS to predict subsequent cognitive changes. Methods: Angiography at enrollment in the SAMMPRIS trial was independently evaluated, blind to clinical data and cognitive testing. Antegrade flow in the symptomatic arterial territory and corresponding collateral flow were scored. Impaired perfusion was defined by poor antegrade and poor collateral flow. Serial testing with the Montreal Cognitive Assessment (MoCA) was done in subjects without aphasia or neglect at baseline, 4 mo, 12 mo and closeout, or until subjects had a clinical stroke endpoint. Results: 207 subjects (median age 61, range 33-81 years; 37% women) had baseline MoCA scores with angiography data on territorial perfusion. Baseline MoCA scores (mean 24.2±4.1) were similar between categories of antegrade flow and collateral circulation. Impaired perfusion was noted in 33/207 (16%). Serial MoCA revealed that changes in cognition over time were different at 4 mo, 12 mo and closeout based on the presence of impaired perfusion at baseline (p&lt;0.001). After more modest (mean MoCA change = 0.5 increase from baseline, p=0.80) early improved cognitive function at 4 mo, those with impaired perfusion had cognitive decline at 12 mo (mean MoCA change, p&lt;0.01) unlike the continued improvement in other subjects. Cognitive changes in those with impaired perfusion were associated with a higher frequency of subsequent stroke in the territory. Conclusions: Impaired perfusion in the symptomatic arterial territory of ICAD predicts cognitive outcomes that may precede recurrent ischemia. Future studies may define the role of noninvasive perfusion imaging in ICAD to predict cognitive trajectories and recurrent stroke.